As shown in Fig. 1f, BIX treatment significantly diminished the growth of EGFR-mutant NSCLC cells (PC9) compared with EGFR-WT NSCLC cells (H460) in vivo. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.